Drug Profile

Research programme: JAK2V617F mutant selective JH2 inhibitors - Prelude Therapeutics

Alternative Names: JAK2V617F JH2 inhibitors - Prelude Therapeutics

Latest Information Update: 28 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Prelude Therapeutics
Class Antineoplastics
Mechanism of Action Janus kinase 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Myeloproliferative disorders

Most Recent Events

04 Nov 2025 Prelude Therapeutics collaborates with Incyte for development of JAK2V617F JH2 inhibitor programme for Myeloproliferative disorders
03 Nov 2025 Preclinical trials in Myeloproliferative disorders in USA (PO)
03 Nov 2025 Pharmacodynamics and adverse events data from preclinical studies for Myeloproliferative disorders released by the Prelude Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com